A Shifting Trend In FDA Form 483 Disclosure Obligations
By Brett Jaffe, Timothy Fitzmaurice and Sierra Shear · August 22, 2025, 5:08 PM EDT
The U.S. District Court for the Southern District of New York's May 19 decision in In re: Checkpoint Therapeutics Securities Litigation extends a streak of dismissals of securities class actions alleging...
To view the full article, register now.